TheEdgeResearch
Home / Stocks / TECH

Bio-Techne Corporation (TECH)

NASDAQ Healthcare Biotechnology
$72.20 ▲ +0.07%
Market Cap
$11.30B
Sector
Healthcare
Industry
Biotechnology
Beta
1.28
52-Wk Range
43.2-72.39
CEO
Kim Kelderman
Country
US
Currency
USD

Bio-Techne Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Minneapolis, MN, US. The stock last traded at $72.20, up 0.07% on the session, giving a market capitalisation of $11.30B. On trailing twelve-month figures it carries a trailing P/E of 61.71, a net margin of 15.0%. Its beta of 1.28 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
61.71
Price / Sales
9.30
Price / Book
5.29
EV / EBITDA
34.72
Gross margin
65.6%
Operating margin
20.5%
Net margin
15.0%
Return on equity
Debt / equity
0.13
Current ratio
4.55
Dividend yield
0.4%
Payout ratio
27.4%
Company profile
Exchange
NASDAQ
Employees
3,100
IPO date
1989-02-09
Headquarters
Minneapolis, MN, US
About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Comparable companies

Bio-Techne Corporation is most often compared with the following Healthcare names:

BMRNCAICORTEXELJAZZMDGLMRNAQGENRNARVMD
More research on TECH
TECH technical analysis TECH TheEdge Score Compare against peers
Open full interactive analysis & DCF →